DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies

Completed

Conditions: Healthy Volunteers

First Posted Date: 2009-10-15

Last Posted Date: 2019-12-05

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 88

Registration Number: NCT00995891

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Phase 2

Completed

Conditions: Airway Inflammation
Severe, Refractory Asthma
Airflow Obstruction

Interventions: Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2009-10-14

Last Posted Date: 2017-09-05

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 15

Registration Number: NCT00994175

Locations: 🇺🇸
INOVA Fairfax Hospital, Falls Church, Virginia, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Statins for Acutely Injured Lungs From Sepsis

Phase 3

Terminated

Conditions: Acute Lung Injury
Sepsis

Interventions: Drug: Placebo
Drug: Rosuvastatin

First Posted Date: 2009-09-17

Last Posted Date: 2016-05-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 745

Registration Number: NCT00979121

Locations: 🇺🇸
McKay-Dee Hospital, Ogden, Utah, United States
🇺🇸
Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States
🇺🇸
Providence Hospital, Everett, Washington, United States

and more 37 locations

Haploidentical PBMC Transplant for Severe Congenital Anemias

Phase 1

Active, not recruiting

Conditions: Sickle Cell Anemia

Interventions: Procedure: PBSC Transplant
Drug: Alemtuzumab
Drug: Sirolimus
Procedure: Low Dose Irradiation
Drug: Cyclophosphamide

First Posted Date: 2009-09-16

Last Posted Date: 2025-01-17

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 23

Registration Number: NCT00977691

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols

Completed

Conditions: Inflammatory Disease
Healthy Volunteers
Autoimmune Disease
Immunologic Disease

First Posted Date: 2009-08-28

Last Posted Date: 2017-10-27

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 587

Registration Number: NCT00968084

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

X-ray Fluoroscopy Fused With Computed Tomography (XFC) Technical Development

Completed

Conditions: Aortic Valve Stenosis

First Posted Date: 2009-08-25

Last Posted Date: 2017-07-02

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT00965679

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Thrombocytopenia

Interventions: Drug: Eltrombopag

First Posted Date: 2009-08-18

Last Posted Date: 2023-11-14

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 30

Registration Number: NCT00961064

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment

Phase 2

Completed

Conditions: Anemia, Aplastic
Anemia, Hypoplastic

Interventions: Drug: h-ATG (ATGAM )
Drug: Cyclosporine (Gengraf )

First Posted Date: 2009-07-23

Last Posted Date: 2021-03-23

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 23

Registration Number: NCT00944749

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Natural History of Bronchiectasis

Recruiting

Conditions: Cystic Fibrosis
Common Variable Immunodeficiency
Autoimmune Disease
Bronchiectasis

First Posted Date: 2009-07-22

Last Posted Date: 2025-05-23

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 900

Registration Number: NCT00943514

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)

Not Applicable

Completed

Conditions: HIV Infections
Pulmonary Complications

Interventions: Other: Smoking Cessation

First Posted Date: 2009-07-07

Last Posted Date: 2016-09-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT00933595

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy